Hubbry Logo
Zika feverZika feverMain
Open search
Zika fever
Community hub
Zika fever
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Zika fever
Zika fever
from Wikipedia

Zika fever
Other namesZika virus disease, Zika, Zika virus infection
Rash during Zika fever infection
Pronunciation
SpecialtyInfectious disease
SymptomsFever, red eyes, joint pain, headache, maculopapular rash, Sometimes none[1][2][3]
ComplicationsGuillain–Barré syndrome, during pregnancy can cause microcephaly in the baby[4][5][6]
DurationShort-term[2]
CausesZika virus mainly spread by mosquitoes, can also be sexually transmitted[2]
Diagnostic methodTesting blood, urine, or saliva for viral RNA or blood for antibodies[1][2]
Differential diagnosisChikungunya, malaria, dengue, leptospirosis, measles[7]
PreventionPermethrin, DEET, picaridin, male condoms[2][8]
TreatmentSupportive care, Generally not needed in mild cases[2]
Deaths≥ 51 (2016–19)[9]

Zika fever, also known as Zika virus disease or simply Zika, is an infectious disease caused by the Zika virus.[1] Most cases have no symptoms, but when present they are usually mild and can resemble dengue fever.[1][4] Symptoms may include fever, red eyes, joint pain, headache, and a maculopapular rash.[1][2][3] Symptoms generally last less than seven days.[2] It has not caused any reported deaths during the initial infection.[4] Mother-to-child transmission during pregnancy can cause microcephaly and other brain malformations in some babies.[5][6] Infections in adults have been linked to Guillain–Barré syndrome (GBS).[4]

Zika fever is mainly spread via the bite of mosquitoes of the Aedes type.[2] It can also be sexually transmitted and potentially spread by blood transfusions.[2][8] Infections in pregnant women can spread to the baby.[5][6][10] Diagnosis is by testing the blood, urine, or saliva for the presence of the virus's RNA when the person is sick, or the blood for antibodies after symptoms are present more than a week.[1][2]

Prevention involves decreasing mosquito bites in areas where the disease occurs and proper condom use.[2][8] Efforts to prevent bites include the use of insect repellent, covering much of the body with clothing, mosquito nets, and getting rid of standing water where mosquitoes reproduce.[1] There is no effective vaccine.[2] Health officials recommended that women in areas affected by the 2015–16 Zika outbreak consider putting off pregnancy and that pregnant women not travel to these areas.[2][11] While there is no specific treatment, paracetamol (acetaminophen) may help with the symptoms.[2] Hospital admission is rarely necessary.[4]

The virus that causes the disease was first isolated in Africa in 1947.[12] The first documented outbreak among people occurred in 2007 in the Federated States of Micronesia.[2] An outbreak started in Brazil in 2015, and spread to the Americas, Pacific, Asia, and Africa.[13] This led the World Health Organization to declare it a Public Health Emergency of International Concern in February 2016.[13] The emergency was lifted in November 2016, but 84 countries still reported cases as of March 2017.[14] The last proven case of Zika spread in the Continental United States was in 2017.[15]

Signs and symptoms

[edit]
Rash on an arm due to Zika fever

Most people who are infected have no or few symptoms.[16] Otherwise the most common signs and symptoms of Zika fever are fever, rash, conjunctivitis (red eyes), muscle and joint pain, and headache, which are similar to signs and symptoms of dengue and chikungunya fever.[17] The time from a mosquito bite to developing symptoms is not yet known, but is probably a few days to a week.[18] The disease lasts for several days to a week. It is usually mild enough for people not to go to a hospital.[1][19]

Due to being in the same family as dengue, there has been concern that it could cause similar bleeding disorders. However that has only been documented in one case, with blood seen in semen, also known as hematospermia.[20]

Guillain–Barré syndrome

[edit]

Zika virus infections have been strongly associated with Guillain–Barré syndrome (GBS), which is a rapid onset of muscle weakness caused by the immune system damaging the peripheral nervous system, and which can progress to paralysis.[21] While both GBS and Zika infection can simultaneously occur in the same individual, it is difficult to definitively identify Zika virus as the cause of GBS.[22] Though Zika virus has been shown to infect human Schwann cells.[23] Several countries affected by Zika outbreaks have reported increases in the rate of new cases of GBS. During the 2013–2014 outbreak in French Polynesia, there were 42 reported cases of GBS over three months, compared to between 3 and 10 annually before the outbreak.[24]

Pregnancy

[edit]
Microcephaly

The disease spreads from mother to child in the womb and can cause multiple problems, most notably microcephaly, in the baby. The full range of birth defects caused by infection during pregnancy is not known, but they appear to be common, with large-scale abnormalities seen in up to 42% of live births.[25][26] The most common observed associations have been abnormalities with brain and eye development such as microcephaly and chorioretinal scarring.[27] Less commonly there have been systemic abnormalities such as hydrops fetalis, where there is abnormal accumulation of fluid in the fetus.[28][29] These abnormalities can lead to intellectual problems, seizures, vision problems, hearing problems, problems feeding and slow development.[30]

Whether the stage of pregnancy at which the mother becomes infected affects the risk to the fetus is not well understood, nor is whether other risk factors affect outcomes.[5][6][10] One group has estimated the risk of a baby developing microcephaly at about 1% when the mother is infected during the first trimester, with the risk of developing microcephaly becoming uncertain beyond the first trimester.[31] Affected babies might appear normal but actually have brain abnormalities; infection in newborns could also lead to brain damage.[32]

Cause

[edit]

Reservoir

[edit]

Zika virus is a mosquito-borne flavivirus closely related to the dengue and yellow fever viruses. While mosquitoes are the vector, the main reservoir species remains unknown, though serological evidence has been found in both West African monkeys and rodents.[33][34]

Transmission

[edit]

Transmission is via the bite of mosquitoes from the genus Aedes, primarily Aedes aegypti in tropical regions. It has also been isolated from Ae. africanus, Ae. apicoargenteus, Ae. luteocephalus,[35] Ae. albopictus,[36][37] Ae. vittatus and Ae. furcifer.[33] During the 2007 outbreak on Yap Island in the South Pacific, Aedes hensilli was the vector, while Aedes polynesiensis spread the virus in French Polynesia in 2013.[38]

Zika virus can also spread by sexual transmission from infected men to their partners.[39][40][41] Zika virus has been isolated from semen samples, with one person having 100,000 times more virus in semen than blood or urine, two weeks after being infected.[42] It is unclear why levels in semen can be higher than other body fluids, and it is also unclear how long infectious virus can remain in semen. There have also been cases of men with no symptoms of Zika virus infection transmitting the disease.[43] The CDC has recommended that all men who have travelled to affected areas should wait at least 6 months before trying to attempt conception, regardless of whether they were ill.[44] To date, there have been no reported sexual transmissions from women to their sexual partners.[41] Oral, anal, or vaginal sex can spread the disease.[45][46]

Cases of vertical perinatal transmission have been reported.[47] The CDC recommends that women with Zika fever wait at least 8 weeks after they start having symptoms of the disease before attempting to conceive.[48] There have been no reported cases of transmission from breastfeeding, but infectious virus has been found in breast milk.[49]

Like other flaviviruses, it could potentially be transmitted by blood transfusion, and several affected countries have developed strategies to screen blood donors.[19][50] The U.S. FDA has recommended universal screening of blood products for Zika.[51] The virus is detected in 3% of asymptomatic blood donors in French Polynesia.[52]

Pathophysiology

[edit]

In fruit flies, microcephaly appears to be caused by the flavivirid virus protein NS4A, which can disrupt brain growth by hijacking a pathway that regulates the growth of new neurons.[53]

Diagnosis

[edit]

It is difficult to diagnose Zika virus infection based on clinical signs and symptoms alone due to overlaps with other arboviruses that are endemic to similar areas.[19][54] The US Centers for Disease Control and Prevention (CDC) advises that "based on the typical clinical features, the differential diagnosis for Zika virus infection is broad. In addition to dengue, other considerations include leptospirosis, malaria, rickettsia, group A streptococcus, rubella, measles, and parvovirus, enterovirus, adenovirus, and alphavirus infections (e.g., chikungunya, Mayaro, Ross River, Barmah Forest, O'nyong'nyong, and Sindbis viruses)."[55]

In small case series, routine chemistry and complete blood counts have been normal in most patients. A few have been reported to have mild leukopenia, thrombocytopenia, and elevated liver transaminases.[56]

Zika virus can be identified by reverse transcriptase PCR (RT-PCR) in acutely ill patients. However, the period of viremia can be short[4] and the World Health Organization (WHO) recommends RT-PCR testing be done on serum collected within 1 to 3 days of symptom onset or on saliva samples collected during the first 3 to 5 days.[38] When evaluating paired samples, Zika virus was detected more frequently in saliva than serum.[56] Urine samples can be collected and tested up to 14 days after the onset of symptoms, as the virus has been seen to survive longer in the urine than either saliva or serum.[57] The longest period of having a detectable level of the virus has been 11 days, and the Zika virus does not appear to establish latency.[33]

Later on, serology for the detection of specific IgM and IgG antibodies to the Zika virus can be used. IgM antibodies can be detectable within 3 days of the onset of illness.[33] Serological cross-reactions with closely related flaviviruses such as dengue and West Nile virus as well as vaccines to flaviviruses are possible.[4][58][59] As of 2019, the FDA has authorized two tests to detect Zika virus antibodies.[60]

Screening in pregnancy

[edit]

The CDC recommends screening some pregnant women even if they do not have symptoms of infection. Pregnant women who have traveled to affected areas should be tested between two and twelve weeks after their return from travel.[61] Due to the difficulties with ordering and interpreting tests for Zika virus, the CDC also recommends that healthcare providers contact their local health department for assistance.[61] For women living in affected areas, the CDC has recommended testing at the first prenatal visit with a doctor as well as in the mid-second trimester, though this may be adjusted based on local resources and the local burden of Zika virus.[61] Additional testing should be done for any signs of Zika virus disease. Women with positive test results for Zika virus infection should have their fetus monitored by ultrasound every three to four weeks to monitor fetal anatomy and growth.[61]

Infant testing

[edit]

For infants with suspected congenital Zika virus disease, the CDC recommends testing with both serologic and molecular assays such as RT-PCR, IgM ELISA and plaque reduction neutralization test (PRNT).[62] RT-PCR of the infant's serum and urine should be performed in the first two days of life.[62] Newborns with a mother who was potentially exposed and who have positive blood tests, microcephaly or intracranial calcifications [63] should have further testing including a thorough physical investigation for neurologic abnormalities, dysmorphic features, splenomegaly, hepatomegaly, and rash or other skin lesions.[62] Other recommended tests are cranial ultrasound, hearing evaluation,[64] and eye examination.[62] Testing should be done for any abnormalities encountered as well as for other congenital infections such as syphilis, toxoplasmosis, rubella, cytomegalovirus infection, lymphocytic choriomeningitis virus infection, and herpes simplex virus.[62] Some tests should be repeated up to 6 months later, as there can be delayed effects, particularly with hearing.[62]

Infant feeding in areas of Zika virus transmission

[edit]

In response to the widespread transmission of the Zika virus during the 2016 outbreak and concerns about viral genetic material detected in breast milk the World Health Organization (WHO) released a Guideline for infant feeding in areas of Zika virus transmission, first in 2016 and updated in 2021, where the evidence showed that despite the detection of Zika virus in breast milk, there is unclear evidence of transmission to the infant, and considering that Zika virus infection among infants is mild, the balance between desirable and undesirable effects favors breastfeeding versus not breastfeeding.[65] According to the 2021WHO guidelines:[65]

  • Infants born to mothers with suspected, probable, or confirmed Zika virus infection or who reside in or have traveled to areas of ongoing Zika virus transmission should be fed according to normal infant feeding guidelines. They should start breastfeeding within one hour of birth, be exclusively breastfed for six months, and have a timely introduction of adequate, safe, and properly fed complementary foods while continuing breastfeeding up to two years of age or beyond.[65]
  • Infants fed with expressed breast milk from mothers with suspected, probable, or confirmed Zika virus infection or who reside in or have traveled to areas of ongoing Zika virus transmission should be fed according to normal infant feeding guidelines (strong recommendation, very-low certainty of evidence).[65]
  • Among infants (0–12 months) affected by complications associated with Zika virus infection, infant feeding practices should be modified (such as adjusting the environment, postural correction, or thickening feeds) to achieve and maintain optimal possible infant growth and development (strong recommendation, very- low certainty of evidence).[65]
  • Mothers and caregivers of infants affected by complications associated with Zika virus (such as feeding difficulties) should receive skilled support from health-care workers to initiate and sustain optimal infant feeding practices[65]

Prevention

[edit]

The virus is spread by mosquitoes, making mosquito avoidance an important element of disease control. The CDC recommends that individuals:[66]

  • Cover exposed skin by wearing long-sleeved shirts and long pants treated with permethrin.[67]
  • Use an insect repellent containing DEET,[68] picaridin, oil of lemon eucalyptus (OLE), or ethyl butylacetylaminopropionate (IR3535)
  • Always follow product directions and reapply as directed
  • If you are also using sunscreen, apply sunscreen first, let it dry, then apply insect repellent
  • Follow package directions when applying repellent to children. Avoid applying repellent to their hands, eyes, or mouth
  • Stay and sleep in screened-in or air-conditioned rooms
  • Use a bed net if the area where you are sleeping is exposed to the outdoors
  • Cover cribs, strollers, and carriers with mosquito netting for babies under 2 months old.

The CDC also recommends strategies for controlling mosquitoes, such as eliminating standing water, repairing septic tanks, and using screens on doors and windows.[69][70] Spraying insecticide is used to kill flying mosquitoes and larvicide can be used in water containers.[1]

Because Zika virus can be sexually transmitted, men who have gone to an area where Zika fever is occurring should be counseled to either abstain from sex or use condoms for 6 months after travel if their partner is pregnant or could potentially become pregnant.[19][39][48] Breastfeeding is still recommended by the WHO, even by women who have had Zika fever. There have been no recorded cases of Zika transmission to infants through breastfeeding, though the replicative virus has been detected in breast milk.[49][71]

When returning from travel, with or without symptoms, it is suggested that prevention of mosquito bites continue for 3 weeks to reduce the risk of virus transmission to uninfected mosquitoes.[66]

CDC travel alert

[edit]

Because of the "growing evidence of a link between Zika and microcephaly", in January 2016, the CDC issued a travel alert advising pregnant women to consider postponing travel to countries and territories with ongoing local transmission of Zika virus.[72] Later, the advice was updated to caution pregnant women to avoid these areas entirely if possible and, if travel is unavoidable, to protect themselves from mosquito bites.[73] Male partners of pregnant women and couples contemplating pregnancy who must travel to areas where Zika is active are advised to use condoms or abstain from sex.[73] The agency also suggested that women thinking about becoming pregnant should consult with their physicians before traveling.[72][74]

In September 2016, the CDC travel advisories included:[75]

  • Cape Verde
  • Many parts of the Caribbean: Anguilla, Antigua and Barbuda, Aruba, The Bahamas, Barbados, Bonaire, British Virgin Islands, Cayman Islands, Cuba, Curaçao, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Puerto Rico, Saba, Saint Saint Barthélemy, Saint Lucia, Saint Martin, Saint Vincent and the Grenadines, Sint Eustatius, Sint Maarten, Trinidad and Tobago, and the U.S. Virgin Islands
  • Central America: Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama
  • Mexico
  • Most of South America: Argentina, Bolivia, Brazil, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, and Venezuela
  • Several Pacific Islands: American Samoa, Fiji, Marshall Islands, Micronesia, New Caledonia, Papua New Guinea, Samoa, and Tonga
  • In Asia: Singapore, Malaysia, Brunei

In December 2020, no active Zika outbreaks were reported by the CDC.[76]

WHO response

[edit]

Both the regional Pan American Health Organization (PAHO) as well as the WHO have issued statements of concern about the widespread public health impact of the Zika virus and its links to GBS and microcephaly.[77][78] The WHO Director-General, Margaret Chan, issued a statement in February 2016 "declaring that the recent cluster of microcephaly cases and other neurological disorders reported in Brazil, following a similar cluster in French Polynesia in 2014, constitutes a Public Health Emergency of International Concern."[13] The declaration allowed the WHO to coordinate international response to the virus as well as gave its guidance the force of international law under the International Health Regulations.[79][80] The declaration was ended in November 2016.[81]

Vaccine

[edit]

As of 2016, there was no available vaccine. Development was a priority of the US National Institutes of Health (NIH), but officials stated that development of a vaccine could take years.[4][19][54][82] To speed new drug development regulatory strategies were proposed by the WHO and NIH.[83][84] Animal and early human studies were underway as of September 2016.[85][86] As of December 2019, there were several vaccine candidates in various stages of development.[87]

Mosquito control

[edit]

Disease control in the affected countries currently centers around mosquito control. Several approaches are available for the management of Aedes aegypti mosquito populations, including the destruction of larval breeding sites (the aquatic pools in which eggs are laid and larvae hatch before mosquito development into flying adults); and, insecticides targeting either the larval stages, adult mosquitoes or both. Additionally, a whole host of novel technologies are under current development for mosquito control and the World Health Organization has recently lent its support for the accelerated development of modern methods for mosquito control such as the use of Wolbachia bacteria to render mosquitoes resistant to the virus, and, the release of sterilized male mosquitoes that breed with wild female mosquitoes to give rise to non-viable offspring (offspring that do not survive to the biting, adult stage).[88]

Oxitec's genetically modified OX513A mosquito was approved by Brazil's National Biosecurity Technical Commission (CTNBio) in April 2014[89] and it was being used to try to combat mosquitoes carrying the Zika virus in the town of Piracicaba, São Paulo in 2016.[90]

In the 1940s and 1950s, the Aedes aegypti mosquito was eradicated on some Caribbean islands and in at least eighteen Latin American countries. Decreasing political will and presumably available money, mosquito resistance to insecticide, and a pace of urbanization that exceeded eradication efforts led to this mosquito's comeback.[91]

Machine learning and Zika virus monitoring

[edit]

Due to the difficulty of diagnosing the Zika virus early, as many cases are asymptomatic, machine learning techniques have emerged as a potentially promising solution for improving the prediction and surveillance of virus outbreaks. This approach would track the virus's spread by analyzing genetic data, media, and climate history to identify environmental changes that allow Aedes mosquitoes to thrive. Such insights could aid in early warning and preventative efforts. However, challenges remain in integrating these methods into healthcare systems and ensuring the data quality used for accurate predictions.[92]

Treatment

[edit]

There is currently no specific treatment for Zika virus infection. Care is supportive with the treatment of pain, fever, and itching.[38] Some authorities have recommended against using aspirin and other NSAIDs as these have been associated with hemorrhagic syndrome when used for other flaviviruses.[4][19] Additionally, aspirin use is generally avoided in children when possible due to the risk of Reye syndrome.[93]

Zika virus was poorly studied until the major outbreak in 2015, and no specific antiviral treatments are available as yet.[19] Advice to pregnant women is to avoid any risk of infection so far as possible, as once infected, there is little that can be done beyond supportive treatment.[94]

Outcomes

[edit]

Most of the time, Zika fever resolves on its own in two to seven days, but rarely, some people develop Guillain–Barré syndrome.[4][95] The fetus of a pregnant woman who has Zika fever may die or be born with congenital central nervous system malformations, like microcephaly.[4]

Some individuals have reported experiencing symptoms similar to those they had during their initial Zika virus infection, such as arthralgia, muscle aches, and fatigue, months after recovery. Although these symptoms are not typical, they can persist for months, though they tend to be less severe than during the acute phase of infection. This underscores the importance of ongoing research to better understand the long-term health effects of contracting the Zika virus.

Epidemiology

[edit]
Countries with active Zika virus transmission as of September 2016

In April 1947, as part of studies sponsored by the Rockefeller Foundation into yellow fever, 6 caged rhesus monkeys were placed in the canopy of the Zika Forest of Uganda.[96] On April 18 one of the monkeys (no. 776) developed a fever and blood samples revealed the first known case of Zika fever.[33][96] Population surveys at the time in Uganda found 6.1% of individuals to be seropositive for Zika.[47] The first human cases were reported in Nigeria in 1954.[97] A few outbreaks have been reported in tropical Africa and some areas in Southeast Asia.[98] Until recently there were no documented cases of Zika virus in the Indian subcontinent,[99] however, the first cases were reported in 2017 from Gujarat state and Tamil Nadu,[100] more cases were reported in Rajasthan state involving an outbreak of 153 reported cases[101] and in a pregnant women living in Kerala state.[102] A 1954 study assessing blood samples from several people from different states found antibodies to Zika in healthy people in India which could indicate past exposure, though it could also be due to cross-reaction with other flaviviruses.[99]

By using phylogenetic analysis of Asian strains, it was estimated that Zika virus had moved to Southeast Asia by 1945.[47] In 1977–1978, Zika virus infection was described as a cause of fever in Indonesia.[103] Before 2007, there were only 13 reported natural infections with Zika virus, all with a mild, self-limited febrile illness.[33][104] As of July 2019, evidence of local transmission from mosquitoes to humans has been reported in a total of 87 countries from four of six WHO Regions; African, Americas, South-East Asia and Western Pacific.[105]

Since the previous epidemiological update in 2019, Kenya and India have been added to the list of countries with confirmed local Zika virus transmission. [106]

Yap Islands

[edit]

The first major outbreak, with 185 confirmed cases, was reported in 2007 in the Yap Islands of the Federated States of Micronesia.[107] A total of 108 cases were confirmed by PCR or serology, and 72 additional cases were suspected. The most common symptoms were rash, fever, arthralgia, and conjunctivitis, and no deaths were reported. The mosquito Aedes hensilli, which was the predominant species identified in Yap during the outbreak, was probably the main transmission vector. While the way of introduction of the virus on Yap Island remains uncertain, it is likely to have happened through the introduction of infected mosquitoes or a human infected with a strain related to those in Southeast Asia.[47][107] This was also the first time Zika fever had been reported outside Africa and Asia.[3] Before the Yap Island outbreak, only 14 human cases had ever been reported.[108]

Oceania

[edit]

In 2013–2014, several outbreaks of Zika were reported in French Polynesia, New Caledonia, Easter Island, and the Cook Islands. The source of the virus was thought to be an independent introduction of the virus from Southeast Asia, unrelated to the Yap Islands outbreak.[47]

Americas

[edit]
Areas of active Zika virus transmission, April 2016

Genetic analyses of Zika virus strains suggest that Zika first entered the Americas between May and December 2013.[109] It was first detected in the Western Hemisphere in February 2014, and rapidly spread throughout South and Central America, reaching Mexico in November 2015.[19][47][110] In 2016 it established local transmission in Florida and Texas.[111][112] The first death in the United States due to Zika occurred in February 2016.[113]

In May 2015, Brazil officially reported its first 16 cases of the illness.[114] Although, a case of illness was reported in March 2015 in a returning traveller.[115] According to the Brazilian Health Ministry, as of November 2015 there was no official count of the number of people infected with the virus in Brazil, since the disease is not subject to compulsory notification. Even so, cases were reported in 14 states of the country. Mosquito-borne Zika virus is suspected to be the cause of 2,400 possible cases of microcephaly and 29 infant deaths in Brazil in 2015 (of the 2400 or so notified cases in 2015, 2165 were under investigation in December 2015, 134 were confirmed, and 102 were ruled out for microcephaly).[116]

The Brazilian Health Ministry has reported at least 2,400 suspected cases of microcephaly in the country in 2015 as of 12 December, and 29 fatalities.[116][117][118][119] Before the Zika outbreak, only an average of 150 to 200 cases per year were reported in Brazil.[120] In the state of Pernambuco the reported rates of microcephaly in 2015 are 77 times higher than in the previous 5 years.[120] A model using data from a Zika outbreak in French Polynesia estimated the risk of microcephaly in children born to mothers who acquired Zika virus in the first trimester to be 1%.[121]

On 24 January 2016, the WHO warned that the virus is likely to spread to nearly all countries of the Americas, since its vector, the mosquito Aedes aegypti, is found in all countries in the region, except for Canada and continental Chile.[122][123] The mosquito and dengue fever have been detected in Chile's Easter Island, some 3,500 km (2,200 mi) away from its closest point in mainland Chile, since 2002.[124]

In February 2016, WHO declared the outbreak a Public Health Emergency of International Concern as evidence grew that Zika is a cause of birth defects and neurological problems.[19][125][126][127] In April 2016, WHO stated there is a scientific consensus, based on preliminary evidence, that Zika is a cause of microcephaly in infants and Guillain–Barré syndrome in adults.[10] Studies of this and prior outbreaks have found Zika infection during pregnancy to be associated with early pregnancy loss and other pregnancy problems.[128][129] In the Americas the number of cases peaked during the first half of 2016 and declined through 2017–2018, with a total of 31,587 suspected, probable, and confirmed cases of ZIKV disease were reported in the Region of the Americas. Of these, 3,473 (11%) were laboratory-confirmed. Transmission persists at low levels in some areas and is not uniformly distributed within countries.[105]

Asia

[edit]

In 2016, imported or locally transmitted Zika was reported in all the countries of Asia except Brunei, Hong Kong, Myanmar and Nepal.[130] Serological surveys have indicated that Zika virus is endemic in most areas of Asia, though at a low level.[130] While there was a sharp rise in the number of cases of Zika detected in Singapore after the 2016 Summer Olympics in Brazil, genetic analysis revealed that the strains were more closely related to strains from Thailand than from those causing the epidemic in the Americas.[131][132][133]

History

[edit]

Origin of the name

[edit]

It is named after the Zika Forest near Entebbe, Uganda, where the Zika virus was first identified.[134]

Microcephaly and other infant disorders

[edit]

Zika virus was first identified in the late 1940s in Kampala, Uganda, Africa, but was first confirmed in Brazil. Since it was first identified, Zika has been found in more than 27 countries and territories.[135] Following the initial Zika outbreak in Northeastern Brazil in May 2015, physicians observed a tremendous surge of reports of infants born with microcephaly, with 20 times the number of expected cases.[136][137] Many of these cases have since been confirmed, leading WHO officials to project that approximately 2,500 infants will be found to have been born in Brazil with Zika-related microcephaly.[138][139]

Proving that Zika causes these effects was difficult and complex for several reasons.[140][141] For example, the effects on an infant might not be seen until months after the mother's initial infection, long after the time when Zika is easily detected in the body.[140] In addition, research was needed to determine the mechanism by which Zika produced these effects.[142]

Since the initial outbreak, studies that use several different methods have found evidence of a link, leading public health officials to conclude that it appears increasingly likely the virus is linked to microcephaly and miscarriage.[142][143] On 1 February 2016, the World Health Organization declared recently reported clusters of microcephaly and other neurological disorders a Public Health Emergency of International Concern (PHEIC).[144] On 8 March 2016, the WHO Committee reconfirmed that the association between Zika and neurological disorders is of global concern.[142]

The Zika virus was first linked with newborn microcephaly during the Brazilian Zika virus outbreak. In 2015, there were 2,782 suspected cases of microcephaly compared with 147 in 2014 and 167 in 2013.[136] Confirmation of many of the recent cases is pending,[145] and it is difficult to estimate how many cases went unreported before the recent awareness of the risk of virus infections.[146]

Brazilian President Dilma Rousseff in a videoconference about the Zika virus at the National Center for Disaster Management

In November 2015, the Zika virus was isolated in a newborn baby from the northeastern state of Ceará, Brazil, with microcephaly and other congenital disorders. The Lancet medical journal reported in January 2016 that the Brazilian Ministry of Health had confirmed 134 cases of microcephaly "believed to be associated with Zika virus infection" with an additional 2,165 cases in 549 counties in 20 states remaining under investigation.[19][147] An analysis of 574 cases of microcephaly in Brazil during 2015 and the first week of 2016, reported in March 2016, found an association with maternal illness involving rash and fever during the first trimester of pregnancy.[148] During this period, 12 Brazilian states reported increases of at least 3 standard deviations (SDs) in cases of microcephaly compared with 2000–14, with the northeastern states of Bahia, Paraíba and Pernambuco reporting increases of more than 20 SDs.[148]

In January 2016, a baby in Oahu, Hawaii, was born with microcephaly, the first case in the United States of brain damage linked to the virus. The baby and mother tested positive for a past Zika virus infection. The mother, who had probably acquired the virus while traveling in Brazil in May 2015 during the early stages of her pregnancy, had reported her bout of Zika. She recovered before relocating to Hawaii. Her pregnancy had progressed normally, and the baby's condition was not known until birth.[149]

In February 2016, ocular disorders in newborns have been linked to Zika virus infection.[150] In one study in Pernambuco state in Brazil, about 40 percent of babies with Zika-related microcephaly also had scarring of the retina with spots, or pigment alteration.[151] On 20 February 2016, Brazilian scientists announced that they had successfully sequenced the Zika virus genome and expressed hope that this would help in both developing a vaccine and in determining the nature of any link to birth defects.[152]

Also in February 2016, rumors that microcephaly is caused by the use of the larvicide pyriproxyfen in drinking water were refuted by scientists.[153][154][155] "It's important to state that some localities that do not use pyriproxyfen also had reported cases of microcephaly", read a Brazilian government statement.[156] The Brazilian government also refuted conspiracy theories that chickenpox and rubella vaccinations or genetically modified mosquitoes were causing increases in microcephaly.[155]

Researchers also suspected that the Zika virus could be transmitted by a pregnant woman to her baby ("vertical transmission"). This remained unproven until February 2016, when a paper by Calvet et al. was published, showing not only the Zika virus genome found in the amniotic fluid but also IgM antibodies against the virus.[157] This means that not only can the virus cross the placental barrier, but also the antibodies produced by the mother can reach the fetus, which suggests that vertical transmission is plausible in these cases. One other study published in March 2016 by Mlakar and colleagues analyzed autopsy tissues from a fetus with microcephaly that was probably related to Zika virus; researchers found ZIKV in the brain tissue and suggested that the brain injuries were probably associated with the virus, which also shed light on the vertical transmission theory.[158] Also in March 2016, first solid evidence was reported on how the virus affects the development of the brain, indicating that it appears to preferentially kill developing brain cells.[159]

The first cases of birth defects linked to Zika in Colombia[160] and in Panama were reported in March 2016.[161] In the same month, researchers published a prospective cohort study that found profound impacts in 29 percent of infants of mothers infected with Zika, some of whom were infected late in pregnancy.[25] This study did not suffer from some of the difficulties of studying Zika: the study followed women who presented to a Rio de Janeiro clinic with fever and rash within the last five days. The women were then tested for Zika using PCR, and then the progress of the pregnancies was followed using ultrasound.[25][162]

Guillain–Barré syndrome

[edit]

A high rate of the autoimmune disease Guillain–Barré syndrome (GBS), noted in the French Polynesia outbreak, has also been found in the outbreak that began in Brazil.[147] Laboratory analysis found Zika infections in some patients with GBS in Brazil, El Salvador, Suriname, and Venezuela,[163] and the WHO declared on 22 March 2016 that Zika appeared to be "implicated" in GBS infection and that if the pattern was confirmed it would represent a global public health crisis.[164]

Research

[edit]

Mechanism

[edit]

Early in the 2015–16 Zika virus epidemic, research was begun to understand how the Zika virus causes microcephaly and other neurological disorders.[165] However, with the 2019 election of Jair Bolsonaro in Brazil, who cut funding for research, and the emergence of the COVID-19 pandemic in early 2020, most Zika-related research projects were abandoned or reduced.[166]

It may involve infection of the primary neural stem cells of the fetal brain, known as neural progenitor cells.[167][29] The main roles of brain stem cells are to proliferate until the correct number is achieved, and then to produce neurons through the process of neurogenesis.[168] Zika proteins NS4A and NS4B have also been shown to directly suppress neurogenesis.[29] Infection of brain stem cells can cause cell death, which reduces the production of future neurons and leads to a smaller brain.[167] Zika also appears to have an equal tropism for cells of the developing eye, leading to high rates of eye abnormalities as well.[29]

In addition to inducing cell death, infection of neural progenitor cells may alter the process of cell proliferation, causing a depletion in the pool of progenitor cells.[169] A large number of cases of microcephaly have been associated with inherited gene mutations, and specifically with mutations that lead to dysfunction of the mitotic spindle. There is some evidence that the Zika virus may directly or indirectly interfere with mitotic function, which may play a role in altering cell proliferation.[170]

Another line of research considers that Zika, unlike other flaviviruses, may target developing brain cells after it crosses the placenta, and considers the resulting damage likely to be the result of inflammation as a byproduct of the immune response to the infection of those cells.[171]

Mosquito control

[edit]

Some experimental prevention methods include breeding and releasing mosquitoes that have been genetically modified to prevent them from transmitting pathogens, or have been infected with the Wolbachia bacterium, believed to inhibit the spread of viruses.[19][172] A strain of Wolbachia helped to reduce the vector competence of the Zika virus in infected Aedes aegypti released in Medellin, Colombia.[173]

Gene drive is a technique for changing wild populations, for instance to combat insects so they cannot transmit diseases (in particular mosquitoes in the cases of malaria and Zika).[174] Another method which been researched aims to render male mosquitoes infertile by nuclear radiation in the hope to reduce populations; this is done with a cobalt-60 gamma cell irradiator.[175] In 2016 the World Health Organization encouraged field trials of transgenic male Aedes aegypti mosquitoes developed by Oxitec to try to halt the spread of the Zika virus.[176]

Potential application in Glioblastoma treatment

[edit]

Recent studies have explored the use of the Zika virus (ZIKV)[177] as a potential treatment for glioblastoma multiforme (GBM), a highly aggressive brain cancer. GBM has a median survival rate of about 15 months due to limited treatment options and high tumor recurrence rates. Oncolytic virotherapy, which uses specific viruses to target and destroy cancer cells, has shown promise as an alternative treatment for GBM.

One study investigated the oncolytic potential of live-attenuated vaccine strains of Zika virus (ZIKV-LAV) against human GBM cells in vitro. The study found that ZIKV-LAV selectively infected and killed GBM cells without affecting terminally differentiated neurons or primary endothelial cells. ZIKV-LAV induced cell death through apoptosis and pyroptosis, two forms of programmed cell death.[178]

This research highlights the potential of ZIKV-LAV as a treatment for GBM through oncolytic virotherapy. However, further clinical trials and research are necessary to assess its efficacy in human patients.

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Zika fever, also known as Zika virus disease, is a mosquito-borne viral infection caused by the , a member of the family, primarily transmitted through the bite of infected or mosquitoes. The virus was first isolated in 1947 from a rhesus monkey in the Zika Forest of , but human infections remained sporadic and mild until large-scale outbreaks emerged in the . Transmission can also occur sexually, via , or congenitally from mother to , though mosquito bites account for the majority of cases in endemic areas. Most infections are asymptomatic or produce mild symptoms lasting 2–7 days, including fever, , , , , and , resembling other arboviral illnesses like dengue or . Severe disease is rare in adults, but infection during carries significant risk of congenital Zika , characterized by , brain calcifications, and other neurological impairments in the due to direct viral invasion of developing neural tissue.30318-8/fulltext) Epidemiological studies, including cohort analyses in and , have established a strong causal link, with maternal infection in the first trimester increasing risk up to 17-fold.30020-8/fulltext) Additionally, Guillain-Barré has been associated with Zika , though at lower incidence. The 2015–2016 epidemic, originating in and spreading to 48 countries in the , marked Zika's emergence as a crisis, with over 1.5 million suspected cases reported in alone and heightened global concern due to travel-related spread. This outbreak prompted the to declare a Public Health Emergency of International Concern in February 2016, focusing response on , , and prevention of sexual and perinatal transmission. No specific antiviral treatment or licensed exists, emphasizing bite prevention and safe sexual practices in affected regions. Since the epidemic's peak, incidence has declined due to and measures, though sporadic cases persist in tropical areas.

Virology and Causation

Viral Characteristics

(ZIKV) is an enveloped virus classified in the genus Flavivirus of the family , featuring a positive-sense, single-stranded of approximately 10.8 kilobases. The encodes a polyprotein of 3,423 that undergoes proteolytic cleavage into three structural proteins—capsid (C), precursor (prM, processed to M), and envelope (E)—and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). The structural proteins form the mature virion, a roughly 50 nm particle with an icosahedral-like symmetry, where 180 copies of E and M proteins organize into rafts on the lipid envelope. The E glycoprotein, glycosylated at Asn154, dimerizes on the virion surface and contains domains I, II, and III in its ectodomain, plus a stem-anchor region; domain II harbors the fusion loop critical for low-pH-induced membrane fusion during entry. virions, approximately 60 nm in size, exhibit spiky protrusions from prM-E heterodimers, which are resolved by cleavage of prM during maturation in the trans-Golgi network. The C protein associates with the genomic to form the nucleocapsid core, interacting with prM-E transmembrane regions in particles. Non-structural proteins support : NS3 functions as a (with NS2B cofactor) and , while NS5 acts as the and methyltransferase for genome capping. initiates with translation of the incoming genomic into polyprotein at the (), followed by processing and formation of double-stranded intermediates in ER-derived cytoplasmic vesicles, yielding new positive-sense genomes for packaging. The 5' and 3' untranslated regions contain conserved stem-loop structures that promote genome cyclization and . Phylogenetically, ZIKV divides into African (encompassing East and West African clades) and Asian lineages, with divergence around 12% between them; the Asian lineage, including strains from , Pacific islands, and the , has driven outbreaks since the and exhibits higher substitution rates than the African lineage. No distinct serotypes exist, unlike in , though intra-lineage clades show adaptive mutations, such as in prM and E proteins, differentiating epidemic strains.

Reservoirs and Transmission Modes

Zika virus circulates in a sylvatic cycle primarily among non-human primates in Africa and Asia, where arboreal Aedes species mosquitoes serve as vectors bridging the virus between primate reservoirs and occasional human spillover infections. In this enzootic maintenance, Old World primates sustain viral persistence without requiring human amplification, as evidenced by serological surveys and isolation from primate tissues in endemic forests. Field studies in Uganda and Senegal have detected neutralizing antibodies in multiple primate species, confirming their role as natural hosts. Emerging evidence indicates potential sylvatic reservoirs in neotropical non-human , with natural infection documented in Brazilian howler monkeys via RT-PCR and during the 2015-2017 outbreak, raising concerns for wildlife-mediated reintroduction in urban areas. Urban transmission establishes an anthropocentric cycle reliant on humans as amplifying hosts and peridomestic mosquitoes, bypassing sylvatic and enabling rapid spread in densely populated tropics. Aedes aegypti functions as the primary vector, exhibiting high vector competence with rates exceeding 80% in experimental feeds using contemporary strains, driven by its anthropophilic biting behavior—preferring human hosts—and proliferation in water-holding containers like tires and flower pots. Transmission dynamics hinge on ingestion of viremic blood (threshold ~10^3-10^4 PFU/mL), followed by viral dissemination to salivary glands within 7-14 days, with peak infectivity aligning with biting peaks that overlap human activity. Aedes albopictus acts as a competent secondary vector, with meta-analyses of global strains showing dissemination and transmission efficiencies of 20-60%, varying by viral and population , though generally lower than A. aegypti due to reduced human-biting preference. Non-vector routes include sexual transmission, with viable isolated from semen up to 188 days post-symptom onset in case reports from returning travelers, facilitating male-to-female and potentially female-to-male spread. Perinatal transmission occurs intrapartum, documented in neonates with shortly after birth from infected mothers, independent of involvement. transmission has been confirmed in four cases during Brazil's 2015-2016 , where donors were yet RNA-positive, underscoring testing needs in endemic blood supplies.

Pathophysiological Mechanisms

Zika virus (ZIKV), a flavivirus, primarily targets neural progenitor cells (NPCs) in the developing brain through attachment and entry mechanisms involving candidate receptors such as on radial glia and other neural cells, though is not strictly required for of NPCs as evidenced by similar in AXL-knockout models. Entry proceeds via clathrin-mediated , followed by low-pH-dependent fusion in endosomes, enabling replication in the of susceptible cells like cortical NPCs. Once inside, ZIKV induces cellular disruption through direct cytopathic effects, including G2/M arrest, activation of caspase-3-mediated , and inhibition of NPC differentiation into neurons, as demonstrated in organoid and models where infected NPCs exhibit reduced proliferation and increased cell death.30084-4) ZIKV evades innate immunity by leveraging nonstructural (NS) proteins to antagonize type I (IFN) signaling; notably, NS5 degrades STAT2, a key transducer of IFN responses, while NS4B suppresses IFN-stimulated and NS2B-NS3 cleaves host factors to dampen antiviral pathways, allowing unchecked in lab-infected neural cultures. This evasion promotes dysregulated inflammation, with infected releasing proinflammatory cytokines such as TNF-α and IL-1β, which exacerbate neuronal damage and contribute to blood-brain barrier (BBB) permeability in animal models through tight junction protein alterations like reduced claudin-5 expression. In contrast to (DENV), another flavivirus with limited neurotropism, ZIKV's enhanced neurovirulence stems from sequence variations, including adaptations in the prM-E region and NS proteins that confer stronger cytopathic effects and preferential NPC targeting, as revealed by comparative genomic analyses and differential host mRNA modulation in infected cells. ZIKV uniquely disrupts regulators like ANKLE2 to impair in progenitors, a mechanism absent in DENV, while its compact structure and positive selection sites in NS genes facilitate neural invasion beyond DENV's vascular focus, per structural and evolutionary studies. These differences, validated in cross-species infection models, underscore ZIKV's capacity for congenital via direct cellular and indirect inflammatory cascades.

Clinical Features

Acute Symptoms

Zika fever typically presents as a mild, self-limited acute illness in symptomatic cases, with approximately 80% of infections remaining based on seroprevalence data from multiple outbreaks. Symptomatic individuals experience an abrupt onset of low-grade fever (37.4–38.0°C), lasting 3–7 days, accompanied by a pruritic starting on the face and spreading to the trunk and extremities, affecting small joints of the hands and feet, non-purulent , , and retro-orbital headache. These symptoms usually resolve within 2 weeks without specific sequelae in immunocompetent adults. Laboratory evaluations in acute symptomatic adults often reveal mild , , and elevated liver transaminases, though findings can be subtle and non-specific. Cohort studies from endemic regions, such as and , report symptom incidence rates of fever (up to 99%), (up to 97%), and (up to 65%) among confirmed cases, underscoring the febrile exanthematous nature of the disease. Differential diagnosis is complicated by significant symptom overlap with co-circulating arboviruses like dengue and , particularly in regions of high transmission. For instance, is prominent in both Zika and chikungunya (affecting >60% of cases in comparative studies), while fever and overlap with dengue in >80% of presentations, contributing to misdiagnosis rates exceeding 50% in settings without laboratory confirmation during co-epidemics. This overlap has led to underreporting of Zika in areas where dengue predominates, as evidenced by serological reassessments in and .

Neurological Sequelae

infection has been associated with Guillain-Barré syndrome (GBS), an acute inflammatory characterized by ascending and potential , with epidemiological evidence indicating a temporal link during outbreaks. In the 2013–2014 outbreak, the observed-to-expected ratio for GBS cases reached 20, with 93% of 42 GBS patients testing positive for Zika IgM antibodies compared to 56% in controls, supporting a strong statistical association under for causality, including temporality (median 6 days between Zika symptoms and GBS onset) and biological gradient.00562-6/fulltext) Similar elevated risks were observed in subsequent outbreaks, such as a 1.23% of GBS among confirmed Zika cases in a of flavivirus-endemic regions, though from prior dengue exposure complicates attribution. The proposed mechanism for Zika-associated GBS involves molecular mimicry, where antibodies against Zika envelope protein epitopes cross-react with gangliosides on peripheral nerves, akin to Campylobacter jejuni-triggered GBS; structural analyses of the Zika E protein glycan loop reveal homology to neural antigens, with anti-ganglioside antibodies detected in affected patients. Direct neuroinvasion is less common but evidenced in rare fatal cases, with confirmed in neural tissues via and , alongside inflammatory infiltrates in the . Other sequelae include acute and , reported in case series with Zika detection in , though incidence remains low (e.g., <1% of infections) and causality is supported primarily by temporal clustering rather than consistent viral isolation. Prospective follow-up studies indicate persistent neurological deficits in a subset of Zika-associated GBS cases, with approximately 20–30% of patients experiencing residual weakness, , or sensory disturbances at one year post-onset, alongside higher rates of and depression compared to non-Zika GBS cohorts. In a Colombian cohort tracked beyond the 2015–2016 epidemic, factors like requirement predicted poorer long-term motor recovery, with showing axonal damage in severe instances. These outcomes underscore the need for extended rehabilitation, as recovery is often incomplete despite intravenous immunoglobulin or , highlighting immune-mediated axonal injury as a key pathological feature.

Pregnancy and Congenital Effects

Congenital Zika syndrome (CZS) encompasses a range of birth defects resulting from intrauterine (ZIKV) infection, primarily characterized by severe , intracranial calcifications, , , and . Additional features often include ocular abnormalities such as macular atrophy and chorioretinal scarring, as well as seizures and . These manifestations arise from ZIKV's for fetal neural progenitor cells, leading to and disrupted cortical development. The risk of CZS is highest following maternal in the first trimester, with meta-analyses estimating fetal loss or severe defects in approximately 5-15% of cases overall, though first-trimester exposures confer up to an 11% rate of or related brain anomalies per CDC surveillance data from 2016 outbreaks. rates reach about 47% in early , decreasing to 28% in the second trimester, enabling placental crossing via paracellular disruption of tight junctions. Later infections carry lower but nonzero risks, with evidence of linked to and peripheral nerve damage even in the third trimester. ZIKV breaches the placental barrier by infecting Hofbauer cells and cytotrophoblasts, triggering inflammatory responses that impair nutrient transfer and directly invade fetal vasculature, culminating in cerebral vascular insufficiency and tissue necrosis. Prenatal ultrasound detects early biomarkers such as progressive ventriculomegaly, periventricular calcifications, and reduced head circumference, with sensitivity for CZS prediction improving when combined with maternal viremia duration exceeding 7 days. Long-term outcomes in CZS-affected children include profound , , and motor impairments, while even asymptomatic exposures elevate risks of subtle neurodevelopmental delays, with cohort studies through 2025 reporting a 2.7-fold increased incidence of adverse events like cognitive deficits by age 3-5 years. Follow-up data indicate persistent challenges, including higher hospitalization rates and nutritional deficits, underscoring the virus's enduring impact on maturation beyond gross structural defects.

Diagnosis and Surveillance

Diagnostic Tests

Diagnosis of Zika virus infection primarily relies on molecular detection of viral during acute , with (RT-PCR) serving as the gold standard for confirming active infection. RT-PCR assays target conserved regions of the genome, such as the NS5 or E genes, and exhibit high sensitivity (up to 95-100% during peak viremia) and specificity when performed within the first 1-2 weeks after symptom onset, though sensitivity declines rapidly thereafter as viral loads drop below detectable thresholds (typically <10^3 copies/mL). Validation studies against culture-isolated virus confirm RT-PCR's reliability, but false negatives occur in up to 30-50% of cases tested beyond 7-10 days post-exposure due to short viremic windows. Serological assays detect host immune responses, with IgM enzyme-linked immunosorbent assays (ELISA) identifying antibodies that appear 3-5 days after symptoms and persist for 2-12 weeks. These assays show variable sensitivity (60-90%) and specificity (70-85%), limited by cross-reactivity with dengue virus antigens, which can yield false positives in endemic areas where prior flavivirus exposure is common. Confirmatory plaque reduction neutralization tests (PRNT) measure virus-specific neutralizing antibodies, with titers ≥10 indicating recent Zika infection when heterologous flavivirus titers are <10, per CDC and WHO guidelines; PRNT remains the serological gold standard despite its labor-intensive nature and requirement for biosafety level 3 facilities. Point-of-care (POC) diagnostics, including isothermal amplification methods like reverse transcription (RT-RPA) and (RT-LAMP), offer rapid detection (under 30-60 minutes) without thermocyclers, achieving sensitivities comparable to RT-PCR in controlled settings (80-95%). However, their deployment in resource-poor areas faces challenges, including lower analytical sensitivity in low-viral-load samples, lack of standardized validation against diverse strains, and logistical barriers like reagent stability in high temperatures and need for trained operators, resulting in inconsistent field performance.

Screening Protocols

The Centers for Disease Control and Prevention (CDC) recommends that healthcare providers assess all pregnant women for possible exposure through history of travel to or residence in areas with active transmission, sexual contact with someone who traveled to such areas, or symptoms consistent with Zika infection. In regions with ongoing Zika transmission, universal screening via nucleic acid testing (NAT) such as reverse transcription polymerase chain reaction (RT-PCR) on serum or urine is advised for asymptomatic pregnant women with frequent exposure, alongside Zika immunoglobulin M (IgM) serology to extend detection beyond the brief viremic window. However, routine testing is not recommended for asymptomatic pregnant women with only infrequent travel-related exposure due to low yield and potential for false negatives, prioritizing cost-effective targeted algorithms based on risk stratification. Testing timing is critical, as Zika viral is detectable in serum for typically less than 2 weeks post-, leading to false negatives if specimens are collected outside this window; testing may extend detection slightly, while IgM can be assessed 2–12 weeks after exposure or symptom onset. For fetal assessment in pregnant women with laboratory-confirmed or possible maternal Zika , RT-PCR on is recommended, particularly when paired with maternal serum and performed after 15 weeks to confirm intrauterine transmission, though it does not predict congenital defects with certainty. Protocols integrate testing with serial fetal ultrasounds every 3–4 weeks to monitor for , calcifications, or growth restriction, enabling risk stratification without relying solely on molecular results. For travelers, the (WHO) and CDC advise preconception counseling for those returning from Zika-endemic areas, recommending women delay for at least 2 months (or longer if symptomatic) and men for 3 months post-exposure to mitigate transmission risk, with symptom-based testing via RT-PCR if illness develops within 2 weeks of return. Pregnant travelers or those planning should avoid nonessential travel to affected regions, and upon return, undergo exposure-based screening similar to residents, emphasizing sexual precautions to prevent secondary transmission. These protocols balance detection sensitivity against resource constraints, as universal post-travel screening lacks cost-effectiveness in low-prevalence settings post-2016 outbreaks.

Challenges in Detection

Approximately 80% of Zika virus infections are , resulting in substantial underreporting and gaps that hinder accurate epidemiological tracking. This silent transmission allows the virus to spread undetected in communities, particularly in regions with limited passive reporting systems, where only symptomatic cases prompt medical seeking. Field studies in endemic areas have revealed seroprevalence rates far exceeding notified cases, underscoring how reliance on clinical presentations alone underestimates true incidence. Co-circulation of Zika with dengue and chikungunya viruses exacerbates misattribution, as overlapping symptoms—such as fever, , , and —complicate syndromic differentiation without laboratory confirmation. Serological cross-reactivity among flaviviruses further inflates diagnostic errors, with IgM antibodies often indistinguishable between Zika, dengue, and related pathogens, leading to false positives or indeterminate results. In co-endemic tropical settings, molecular assays like RT-PCR are essential for specificity during acute , yet their narrow detection window (typically 3–14 days post-onset) limits utility if testing is delayed. Outbreak responses face diagnostic delays due to logistical and infrastructural constraints, especially in resource-limited tropical regions where capacity is strained. Recent 2024 Zika resurgence reports from highlighted bottlenecks in availability, trained personnel, and chains for sample , prolonging times amid surging caseloads. These delays not only impede timely measures but also amplify transmission in under-resourced settings with high vector density. Retrospective assessment of past Zika exposures via is particularly unreliable, as persistent antibodies cross-react with prior flavivirus immunities, rendering plaque reduction neutralization tests (PRNT) inconclusive without paired acute-convalescent samples. This limitation complicates attributing historical infections to congenital outcomes or neurological sequelae, as serological evidence alone cannot reliably distinguish Zika-specific immunity from responses. Consequently, serosurveys in post-outbreak cohorts often overestimate or underestimate true exposure rates without orthogonal virologic data.

Treatment and Management

Supportive Therapies

Treatment of Zika virus disease is supportive, as no specific antiviral medications are approved for use as of 2025. Patients are advised to rest and maintain adequate hydration to manage mild symptoms such as fever, , and , which typically resolve within 2 to 7 days. For fever and pain relief, acetaminophen is recommended, while aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen should be avoided until is ruled out, due to the increased risk of hemorrhagic complications associated with NSAIDs in dengue cases, which often co-circulate with Zika. Hospitalization is reserved for severe cases involving requiring intravenous fluids or neurological manifestations like Guillain-Barré syndrome, with close monitoring for symptom progression. The disease is predominantly self-limiting, with over 80% of infections either asymptomatic or resulting in mild illness that resolves without intervention, though rare severe outcomes necessitate vigilant clinical oversight.

Management in Pregnancy

Pregnant individuals with laboratory-confirmed or possible Zika virus infection require enhanced fetal monitoring to detect congenital Zika syndrome (CZS), which includes microcephaly, brain calcifications, and limb contractures. Serial ultrasound examinations, performed every 3-4 weeks starting after the first trimester, assess fetal head circumference, brain structure, amniotic fluid volume, and growth parameters, with findings of microcephaly (head circumference below the third percentile) or ventriculomegaly indicating higher CZS risk. If ultrasound abnormalities are detected, amniocentesis for Zika virus RNA detection via reverse transcription polymerase chain reaction (RT-PCR) on amniotic fluid is recommended, particularly after 20 weeks gestation, to confirm fetal infection, though sensitivity varies and negative results do not exclude CZS. Counseling on continuation or interruption should emphasize empirical CZS probabilities, with conferring a 5-14% overall risk of CZS and 4-6% risk of , risks highest (up to 10-fold) with first- or second-trimester exposure based on cohort data from endemic areas. Providers must discuss these outcomes neutrally, noting that most exposed fetuses (86-95%) do not develop CZS, while severe cases carry lifelong neurological impairments, without assuming moral imperatives for any choice. Multidisciplinary input from maternal-fetal medicine specialists, neurologists, and geneticists informs decisions, evaluating and PCR results against baseline population risks of anomalies unrelated to Zika. If fetal growth restriction or preterm delivery risks arise—though Zika primarily links to small-for-gestational-age neonates rather than —standard antenatal corticosteroids (betamethasone or dexamethasone) are administered between 24 and 34 weeks to promote lung maturation, per established preterm protocols, as no Zika-specific contraindications exist. is advised post-delivery even after maternal Zika , as indicates virus transmission via milk is rare and infrequent, with nutritional and immunological benefits to the outweighing theoretical risks, particularly after maternal resolves (typically within weeks). Ongoing multidisciplinary postpartum evaluation ensures coordination for potential neonatal needs without overlapping post-birth interventions.

Long-Term Care for Affected Infants

Infants diagnosed with congenital Zika syndrome (CZS) from the 2015-2016 outbreaks require multidisciplinary long-term care focused on mitigating severe neurodevelopmental impairments, including , , and sensory deficits observed in cohort follow-ups extending to 2025. Physical and occupational therapies form the cornerstone of interventions, targeting joint contractures in to enhance mobility and postural control, as demonstrated in case reports and Brazilian rehabilitation practices for CZS-affected children. Feeding support, including specialized nutritional management for and breastfeeding difficulties prevalent in over 70% of CZS cases, is critical to address growth faltering documented in 5-year follow-ups. Cognitive and motor delays, with IQ equivalents often below 50 in severe cases, necessitate enrollment in programs tailored to profound intellectual disabilities, as evidenced by neurodevelopmental assessments in exposed cohorts. Mortality among severe CZS infants reaches approximately 10% in the first few years, with a rate ratio 11.3 times higher than unaffected peers up to 36 months, primarily due to respiratory and neurological complications. Lifelong monitoring protocols include regular screening for , affecting up to 50% of CZS children through EEG and clinical evaluation, alongside ophthalmologic and audiologic assessments for vision and hearing losses that impair further development without corrective aids like eyeglasses. In resource-limited regions like , where most cases originated, families report catastrophic health expenditures exceeding 40% of income and geographic barriers to rehabilitation services, highlighting ongoing debates over public funding allocation for sustainable CZS support systems.

Prevention and Control

Vector Management

Vector management for Zika fever primarily targets and mosquitoes through integrated approaches emphasizing source reduction, chemical interventions, and emerging biological techniques. Source reduction involves the physical elimination of breeding sites, such as discarding water-holding containers and covering storage vessels, which disrupts larval development and has been a cornerstone of control efforts in endemic areas. Larvicides like temephos, an applied to aquatic habitats, target immature stages and have demonstrated reductions in larval densities, though evidence from randomized trials indicates variable impact on adult populations and disease incidence due to delayed effects. Adulticides, typically pyrethroids or delivered via ultra-low volume spraying or fogging, provide rapid knockdown of flying adults but require repeated applications to sustain suppression, with combined larvicide-adulticide strategies showing up to 70-80% reductions in mosquito captures in outbreak zones. Efficacy assessments from field trials highlight the limitations of standalone chemical methods, particularly against A. aegypti's behavior of breeding in small, artificial indoor containers and biting during daylight hours indoors, which reduces exposure to outdoor spraying. Insecticide resistance, documented in multiple Aedes populations, further diminishes adulticide effectiveness, necessitating rotation of chemical classes within integrated vector management (IVM) frameworks. Cost-benefit analyses of IVM in Zika-affected regions, including larvicide applications and source reduction, estimate societal savings of $100-150 per averted disability-adjusted life year (DALY), though these gains depend on community compliance and sustained funding. The sterile insect technique (SIT), involving mass release of irradiated sterile males to compete with wild males, has shown promise in pilot trials for A. aegypti suppression relevant to Zika control. In a study, weekly releases over 12 months reduced wild adult densities by up to 79% and egg indices by 59% in intervention areas, outperforming chemical controls in precision but requiring high release ratios (10:1 sterile-to-wild). Brazilian IVM during the 2015-2016 outbreak integrated SIT trials with conventional methods, achieving localized population crashes but facing scalability issues due to Aedes fitness costs on modified insects and uneven coverage in urban slums. Similar challenges persisted in Pacific islands like , where early Zika responses emphasized source reduction amid limited chemical efficacy against container-breeding habits. Overall, IVM outcomes underscore the need for tailored, multi-tool strategies to counter Aedes adaptability and resistance.

Individual Precautions

Individuals at risk of Zika virus exposure, including travelers and residents in endemic areas, should prioritize personal protection against Aedes mosquito bites, which primarily transmit the virus during daytime hours. Effective measures include applying EPA-registered insect repellents containing DEET (at concentrations of 20-30% for adults), picaridin, IR3535, oil of lemon eucalyptus, or para-menthane-diol to exposed skin and clothing, as these provide repellency lasting several hours depending on formulation and activity level. Wearing loose-fitting, long-sleeved shirts, long pants tucked into socks or boots, and hats treated with permethrin insecticide further reduces bite risk, while staying indoors during peak mosquito activity (dawn and dusk) or in air-conditioned environments with intact window and door screens minimizes exposure. These steps should continue for at least three weeks after returning from Zika-risk areas, even without symptoms, to prevent onward transmission if infected. To mitigate sexual transmission, which can occur via semen, vaginal fluids, or other bodily secretions from infected individuals regardless of symptoms, exposed persons should abstain from sexual activity or use or condoms correctly and consistently during vaginal, anal, or , including with shared sex toys; dental dams are recommended for oral-genital contact. For men with possible Zika exposure through travel or residence in risk areas, precautions should extend at least three months from return date, symptom onset, or diagnosis; for women, at least two months under the same triggers. RNA has been detected in up to 69 days post-symptom onset in some cases, with infectious virus persisting longer than in blood, underscoring the need for extended vigilance, particularly for partners planning . Travelers to areas with current or historical Zika transmission should consult CDC categories: in Category 1 (active outbreaks with Travel Health Notices), pregnant individuals must avoid entirely, and conception should be deferred until after the specified sexual transmission precaution period; in Category 2 (past transmission without recent cases), pregnancy planning should be delayed post- if concerns exist, with healthcare provider consultation advised for personalized assessment. As of 2025, no Category 1 areas are designated, but vigilance remains for Category 2 regions like parts of the and Pacific. At the household level, individuals can reduce local populations by eliminating breeding sites through weekly emptying, scrubbing, and drying containers holding water (e.g., flower pots, buckets, tires), covering rain barrels with tight lids, and maintaining clean gutters; installing or repairing fine-mesh screens on windows, doors, and vents prevents entry. These actions complement personal repellency, targeting and A. albopictus mosquitoes that breed in small, artificial water collections near homes.

Vaccine and Therapeutic Prospects

As of 2025, no Zika virus vaccine has received regulatory approval, despite active research following the 2015-2016 pandemic. Development efforts have focused on nucleic acid-based platforms, including DNA, RNA, and mRNA vaccines, as well as inactivated and viral-vectored candidates, with approximately 16 vaccines advancing to phase 1 or phase 2 clinical trials.00750-3/abstract) These candidates aim to elicit neutralizing antibodies targeting the virus's envelope protein, but challenges in demonstrating efficacy during low-incidence periods have delayed progression to licensure. Moderna's mRNA-1893 , an mRNA-based candidate, completed phase 1 trials demonstrating safety, tolerability, and induction of robust neutralizing responses in healthy adults after two doses. A phase 2 randomized, observer-blind study for dose confirmation began enrollment, but as of early 2024, indicated it would not advance further without additional external funding due to shifting priorities and funding constraints. Similarly, Bharat Biotech's BBV121, a purified inactivated adjuvanted with , completed phase 1 clinical trials by August 2024, showing and protection against Asian and African strains in preclinical mouse models. Monoclonal antibody therapies remain primarily in preclinical or early-phase development, with three candidates entering phase 1 trials by 2025.00750-3/abstract) For instance, the human ZIKV-195 has demonstrated potent neutralizing activity and post-exposure therapeutic efficacy in models, reducing and fetal transmission. These approaches target conserved epitopes to block viral entry but face hurdles in scalability and delivery for outbreak response. A major immunological challenge is (ADE), where cross-reactive antibodies from prior exposure—prevalent in endemic areas—may exacerbate Zika infection by facilitating viral entry into Fc receptor-bearing cells. This risk, observed in flavivirus trials like Dengvaxia, necessitates candidates that induce type-specific, non-enhancing immunity, particularly for pregnant women to prevent congenital Zika . Post-outbreak decline in cases has further complicated large-scale efficacy trials, prompting calls for alternative endpoints like immunogenicity correlates of protection.00750-3/abstract)

Public Health Interventions

In response to the 2015-2016 Zika virus outbreak, the (WHO) declared clusters of and neurological disorders associated with Zika a Emergency of International Concern (PHEIC) on February 1, 2016, facilitating coordinated international efforts such as accelerated research, diagnostic development, and resource mobilization across affected regions. This declaration prompted national governments, particularly in and other countries, to implement large-scale measures, including aerial and ground-based fogging () targeting mosquitoes; however, post-outbreak evaluations revealed mixed compliance and efficacy, with persistent challenges from mosquito resistance, indoor breeding sites resistant to space spraying, and incomplete coverage in urban slums. The PHEIC status was terminated on November 18, 2016, after evidence showed declining transmission rates, shifting focus to long-term integration of Zika into routine surveillance rather than emergency-only responses. Travel alerts and advisories issued by the WHO and U.S. Centers for Control and Prevention (CDC) from early 2016 urged pregnant women to avoid or postpone trips to endemic areas, aiming to curb imported cases and sexual transmission; while these measures likely reduced some importation risks in non-endemic regions, they imposed substantial economic burdens on tourism-reliant economies, with projections estimating up to $63.9 billion in lost revenues across due to canceled visits and broader reputational damage. Empirical assessments indicate limited overall prevention of local outbreaks, as sustained transmission depended more on competent local vectors than initial seeding events, and overly restrictive policies risked exacerbating fiscal strains without proportionally mitigating spread. Enhanced surveillance networks, coordinated by the (PAHO) and CDC, expanded syndromic monitoring, laboratory confirmation, and genomic sequencing during the PHEIC, enabling real-time tracking of over 48 countries with autochthonous transmission by December 2016; these systems revealed substantial underreporting, with passive case detection capturing only a fraction of infections due to mild symptoms. Post-2017, Zika cases declined sharply—by over 90% in the Americas—attributed primarily to population-level immunity from prior infections and potential cross-protective effects from dengue exposure, rather than decisive vector interventions, as Aedes populations rebounded in many areas absent sustained control. This underscores limitations in emergency-driven campaigns, with evaluations recommending integrated, community-based strategies over reactive fumigation to address causal drivers like and vector ecology for future arboviral threats.

Epidemiology

Early Outbreaks

The Zika virus was first isolated on April 14, 1947, from the serum of a sentinel rhesus monkey exhibiting fever during routine yellow fever surveillance in the Zika Forest near Entebbe, Uganda; no human cases were identified at that time, but the isolation established the virus's presence in a sylvatic cycle involving primates and mosquitoes.30010-X/fulltext) Serological surveys in 1952 provided the earliest evidence of human exposure, detecting neutralizing antibodies to Zika virus in residents of Uganda and Tanzania, though infections remained subclinical or indistinguishable from other febrile illnesses. The first confirmed human isolation followed in 1954 from the serum of a 10-year-old girl in eastern Nigeria during an outbreak of jaundice, where virus was recovered from one of three patients tested, confirming mild symptomatic infection but no severe outcomes. From the 1950s through the early 2000s, Zika circulated endemically in and , with sporadic human cases reported in countries including , , and ; however, underreporting was prevalent due to the virus's typically mild manifestations—such as transient , low-grade fever, , and —which overlapped with dengue and other arboviral syndromes, and because many infections (estimated 80% or more) were .30010-X/fulltext) Seroprevalence data from nonhuman underscored sustained enzootic transmission, with antibodies detected in up to 16% of wild African green monkeys ( spp.) in and other species across and , indicating reservoir maintenance by peridomestic and sylvatic species like Aedes africanus. The first recognized outbreak beyond and began in April 2007 on Yap Island, , affecting an estimated 185 residents (out of a population of about 11,000) with acute illness characterized by (92%), (72%), and (50%); retrospective serological surveys revealed IgM positivity in 14% of tested individuals, confirming Zika as the etiologic agent and marking the virus's introduction to the Pacific via likely human-mosquito-human amplification by Aedes henseli. No hospitalizations or deaths were reported, reinforcing the baseline of low-severity disease prior to later associations with neurological complications.

2015-2016 Pandemic

The 2015–2016 pandemic initiated with confirmed autochthonous transmission in on May 15, 2015. emerged as the epicenter, experiencing an estimated 440,000 to 1,300,000 suspected cases in 2015. Key drivers included the efficient vector competence of mosquitoes, that proliferated breeding sites in densely populated areas, and immunological naivety in the , where prior exposure to Zika had been negligible, allowing unchecked epidemic growth. The concurrent 2015–2016 El Niño phenomenon exacerbated transmission by modifying rainfall patterns, thereby boosting mosquito populations through enhanced breeding opportunities. A dramatic rise in cases among infants born to infected mothers marked the outbreak's severity, with 4,180 suspected instances reported nationwide by December 2015, concentrated in the northeast. This surge prompted to declare a national on November 11, 2015. The virus disseminated swiftly, achieving autochthonous transmission in 48 countries and territories within the by December 15, 2016, alongside detections in 72 countries and territories globally. In , Guillain-Barré syndrome cases spiked during the epidemic, with an outbreak documented from October 2015 to April 2016 in areas like , where incidence rose markedly—up to tenfold in older age groups—beyond typical annual averages of approximately 19 cases per month. Across the , the period from May 2015 to December 2016 yielded 707,133 suspected Zika cases.

Post-2017 Trends and Recent Activity

Following the 2015-2016 global peak, reported disease cases declined sharply worldwide, with a reduction exceeding 90% by 2018 compared to prior highs, though low-level transmission persists in endemic areas of the and parts of . In the , preliminary indicated approximately 55,813 suspected cases in 2023, with about 11% laboratory-confirmed, primarily in countries like where co-circulation with dengue and complicates detection. By mid-2024, the reported over 25,000 confirmed cases across the region for the year to date, reflecting a 75% decrease in early-year incidence compared to 2023 but underscoring ongoing sporadic clusters amid vector abundance. In Asia, transmission remained focalized, with notable 2024 outbreaks in , including a large cluster in , , from June to September, contributing to 151 total national cases, of which 140 were in alone by late November, affecting 63 pregnant women and resulting in five fatalities. Smaller reports emerged from , highlighting intermittent resurgence in urban settings with mosquito proliferation. In the United States, cases have been limited to travel-associated infections, with only 7 reported among international travelers in 2023 and 19 in 2024, and preliminary 2025 data from the CDC's ArboNET system indicating similarly low numbers without evidence of sustained local mosquito-borne transmission since 2017. Projections suggest potential for localized re-emergence, as post-pandemic in affected regions hovers around 50%, below the estimated 65% threshold required to suppress outbreaks, allowing viral reintroduction via travel. Climate variability and urbanization are anticipated to expand suitable habitats for , with models forecasting up to a 20% rise in transmission risk for Zika and similar arboviruses over the next three decades due to warmer temperatures and denser human-mosquito interfaces. Enhanced in high-risk areas remains essential to monitor waning immunity and environmental drivers.

History

Discovery and Initial Reports

The Zika virus was first isolated in 1947 from the serum of a sentinel rhesus monkey (designated No. 766) during surveillance in the Zika Forest near , . On April 18, 1947, the monkey, caged on a tree platform to monitor arboviral activity, developed a fever, prompting of its blood into mice, from which the novel virus was recovered and distinguished from yellow fever virus through cross-neutralization tests.30010-X/fulltext) In 1948, the virus was subsequently isolated from Aedes africanus mosquitoes trapped in the same forest, establishing its transmission cycle involving primate-mosquito vectors. Initial virological characterization classified Zika virus as a member of the Flaviviridae family, genus Flavivirus, based on morphological, antigenic, and biophysical properties observed in early electron microscopy and serological assays. It was grouped into the Spondweni serocomplex due to cross-reactivity with Spondweni virus, though subsequent analyses revealed phylogenetic divergence, with Zika forming a distinct clade supported by nucleotide sequence differences in the envelope protein and non-structural genes. Serological evidence of human infection emerged in 1952 from surveys in and the United Republic of , where antibodies were detected in individuals using hemagglutination-inhibition tests. From the through the , sporadic human cases were reported across and parts of , primarily identified via seroprevalence studies rather than virus isolation, with limited clinical descriptions of mild, self-limiting febrile illness and scant genomic data due to technological constraints at the time. Full genome sequencing of Zika strains was not achieved until the early 2000s, enabling precise phylogenetic mapping that confirmed its African origins and divergence from related flaviviruses.

Naming and Phylogenetic Origins

The Zika virus derives its name from the Zika Forest in , , where it was first isolated on April 18, 1947, from the serum of a febrile monkey used as a sentinel in yellow fever research. The term "Zika" originates from the language, meaning "overgrown," reflecting the dense forest environment. The associated disease, characterized by mild fever and , became known as Zika fever to distinguish it from more severe arboviral illnesses. Phylogenetically, (ZIKV) is classified within the genus Flavivirus of the family Flaviviridae, sharing close relation to dengue and viruses. Genomic analyses reveal two primary lineages—African and Asian—that diverged from a common East African ancestor around the late 19th or early . The African lineage predominates in sylvatic cycles involving non-human primates and forest-dwelling mosquitoes like Aedes africanus, with limited human spillover. In contrast, the Asian lineage, circulating since at least the 1950s in , has adapted to urban enzootic transmission via , facilitating human epidemics. Evolutionary shifts in the Asian lineage, including codon usage biases in the NS1 gene favoring host expression and potential alterations in protein , have enhanced viral fitness for mosquito- cycles without altering core sylvatic traits. Serological surveys confirm ZIKV's natural zoonotic reservoir in , with antibodies detected in African non- and neotropical , underscoring enzootic origins predating and refuting unsubstantiated lab-origin hypotheses.

Recognition of Severe Outcomes

During the Zika virus outbreak in French Polynesia from October 2013 to April 2014, clinicians noted an unprecedented surge in Guillain-Barré syndrome (GBS) cases, prompting a retrospective case-control study that identified recent Zika infection in 98% of GBS patients compared to 41% of controls, yielding an adjusted of 37.8 for the association.00562-6/fulltext) This study, published in 2016, marked the initial empirical recognition of Zika's potential to trigger severe neurological complications beyond its typically mild febrile illness. In , reports of clusters emerged in late 2015, particularly in northeastern states like , leading to retrospective analyses that confirmed RNA in samples from two pregnant women whose fetuses exhibited via ultrasound.00095-5/fulltext) These findings, corroborated by genomic sequencing of the virus from fetal tissues, provided direct evidence of and fetal disruption, shifting perceptions from Zika as a benign to one capable of congenital malformations. These associations triggered the World Health Organization's declaration of a Public Health Emergency of International Concern on February 1, 2016, based on spatiotemporal clustering, biological plausibility, and consistency with experimental data.-regarding-microcephaly-other-neurological-disorders-and-zika-virus) Independent reviews applied —emphasizing temporality, strength of association, and specificity—to conclude that the evidence thresholds for Zika as a cause of GBS and were met, justifying escalated global surveillance and response.

Research Advances

Mechanistic Insights

non-structural proteins NS2A and NS4A have been implicated in disrupting proliferation through interference with mitotic processes. NS2A alters biogenesis and mitotic spindle orientation, leading to defects and reduced in cortical progenitors, as demonstrated in induced pluripotent stem cell-derived models. Similarly, NS4A and NS4B deregulate the Akt-mTOR pathway, inhibiting and inducing in fetal neural stem cells, thereby contributing to diminished brain organoid size.30214-4) Post-2016 investigations further revealed that Zika infection triggers in neural progenitors via unscheduled mitotic entry amid DNA damage, selectively depleting these cells without broadly affecting differentiated neurons. Animal models developed after 2016 have mechanistically recapitulated congenital Zika syndrome (CZS) features, validating these cellular disruptions . In immunocompromised models, intrauterine Zika exposure at early gestational stages results in , fetal growth restriction, and due to of neural precursors and vascular defects in the developing brain. Non-human primate studies, particularly in rhesus macaques, confirm , fetal brain infection, and neuropathological outcomes like calcifications and mirroring human CZS, with viral persistence in fetal tissues correlating to severity. These models highlight timing-dependent vulnerability, where mid-gestation infection maximizes progenitor loss and cortical thinning. Immune dynamics reveal a balance between protective T-cell mediated clearance and risks from (ADE). + T cells targeting conserved flavivirus epitopes effectively limit Zika replication in neural tissues without ADE susceptibility, as evidenced in mouse challenge studies where T-cell vaccines conferred sterilizing immunity. Conversely, sub-neutralizing antibodies from prior dengue exposure enhance Zika entry via Fcγ receptors on myeloid cells, amplifying and potentially exacerbating neurotropism in co-circulation settings. cohort data post-2016 outbreaks indicate that T-cell responses inversely correlate with disease severity, underscoring their primacy over in containing . Comparative genomics with non-neurotropic flaviviruses like dengue and West Nile identifies Zika-specific adaptations driving neural . Zika exhibits unique structures that facilitate bipartite molecular interactions, enhancing replication in neural stem cells while restricting it in other lineages, unlike dengue's broader cellular permissiveness. Host-protein interaction mapping reveals Zika's preferential engagement of neural-specific pathways, such as those involving septin-2 cleavage by viral , promoting cytoskeletal disruption absent in comparative flaviviruses.31553-8) Phylogenetic shifts in Asian lineage strains, including NS1 glycosylation motifs, correlate with enhanced blood-brain barrier crossing compared to African ancestors or non-neuroinvasive relatives.

Experimental Models

Human (iPSC)-derived s have emerged as a key model for studying (ZIKV) neuropathogenesis, particularly its impact on neural progenitor cells. These three-dimensional structures mimic early human cortical development and have demonstrated ZIKV replication preferentially in neural progenitors, leading to , reduced proliferation, and disrupted . In experiments conducted in 2016, of cerebral organoids with contemporary ZIKV isolates resulted in measurable cell death and stunted organoid growth, correlating with observed phenotypes in vivo.30461-1) Such models have advanced mechanistic insights by revealing ZIKV-induced premature differentiation of progenitors and activation of innate immune pathways like Toll-like receptor 3, though variability in organoid complexity and efficiency poses challenges to across labs. Non-human primate (NHP) models, including rhesus and common marmosets, provide systems to investigate of ZIKV from to , closely recapitulating human gestational timelines and placental architecture. Studies from 2016 onward showed subcutaneous or intravaginal in pregnant NHPs leading to fetal , placental inflammation, and brain lesions, with virus detectable in and fetal tissues up to several weeks post-infection. For instance, African-lineage ZIKV strains crossed the chorioamniotic membrane efficiently, inducing teratogenic effects like reduced fetal head circumference, though outcomes varied by gestational timing and viral dose. However, these models exhibit limitations in scalability to human , as NHP pregnancies do not fully replicate the spectrum of congenital Zika severity, and inter-animal variability in immune responses hinders consistent replication of findings. The 2015-2016 ZIKV outbreak spurred surges in research funding from agencies like the NIH, accelerating adoption of these models while prompting ethical reevaluations of NHP use due to their phylogenetic proximity to humans and welfare concerns. Pre-outbreak reliance on less relevant models shifted toward NHPs for studies, justified by superior translational fidelity, yet critiques highlight over-reliance on small cohort sizes (often n=4-8 dams) that amplify issues from infection dynamics. Post-outbreak guidelines emphasized minimizing NHP numbers through refined endpoints and integration with in vitro alternatives like organoids, balancing scientific urgency against ethical imperatives to avoid unnecessary suffering.

Innovative Applications

Zika virus (ZIKV) has demonstrated preliminary oncolytic potential against , a highly aggressive , primarily through selective infection and lysis of glioblastoma stem cells (GSCs), which drive tumor recurrence and resistance to conventional therapies. This selectivity arises from elevated expression of entry receptors such as and αvβ5 on GSCs and cells, enabling ZIKV to preferentially target malignant neural progenitors while sparing differentiated neurons in preclinical models. studies have shown ZIKV inducing rapid cytopathic effects, including via pyroptosis pathways like GSDMD cleavage, reducing GSC viability and proliferation without equivalent toxicity to non-cancerous cells. Extensions to animal models, such as orthotopic xenografts of GBM, have confirmed ZIKV's efficacy in attenuating tumor growth and extending survival, with intratumoral administration leading to up to 70% survival rates when combined with immune-modulating strategies. Oncolytic effects are enhanced by ZIKV's ability to trigger proinflammatory responses, including increased + T cell infiltration and activation within the , fostering antitumor immunity independent of direct in all cases. However, ZIKV's inherent neurotropism raises concerns, as it can cross the blood-brain barrier and infect neural tissues, potentially exacerbating or causing unintended damage; attenuated strains, such as live-attenuated candidates (e.g., ZIKV-LAV DN-1), mitigate this by retaining oncolytic potency while reducing pathogenicity in non-tumor cells. As of 2025, applications remain confined to preclinical stages, with no ongoing human clinical trials reported for ZIKV-based oncolytic therapy in , distinguishing these efforts from development aimed at preventing infection. Systematic reviews of over a dozen studies emphasize ZIKV's promise as an adjunct to and radiotherapy but highlight the need for further optimization to address vector delivery challenges and long-term in immunocompromised patients. Ongoing explores ZIKV for enhanced specificity, such as SOX2-dependent targeting, to harness its for GSCs while minimizing off-target effects.

Controversies and Critiques

Causality Debates on Microcephaly

Early investigations into the outbreak in , beginning in 2015, revealed an association between maternal and clusters of cases, prompting debates over amid initial uncertainties about viral and prior underreporting of birth defects. Application of the provided a framework for evaluation: was established through studies showing RNA in fetal neural tissues from cases where maternal infection preceded birth, with no reverse causation possible. Strength of association was robust, with cohort studies reporting odds ratios exceeding 70 for in Zika-exposed pregnancies after confounder adjustment, far surpassing typical thresholds for causal inference.30727-2/fulltext) Biological gradient was supported by dose-response patterns, including higher risks with first-trimester infections and correlations between viral load in and severity of cranial defects, as evidenced by genomic detection of replicating Zika in affected brains. Alternative explanations, such as correlations with pyriproxyfen larvicide use in water supplies, were proposed but refuted by spatial analyses showing hotspots in untreated areas and absence of teratogenic mechanisms at exposure levels; controlled epidemiological data confirmed no independent link after accounting for Zika distribution. Claims of chronic underdiagnosis inflating the 2015 surge—citing baseline rates around 0.6 per 10,000 births—were countered by ninefold increases to 5.5 per 10,000, validated by enhanced and direct viral genomic in cases lacking prior diagnostic artifacts. Persistent fringe , including assertions of a post-attribution "diagnostic crash" implying artifactual epidemics, lacks empirical substantiation, as declining cases aligned with waning Zika transmission rather than reporting changes, with longitudinal cohorts affirming sustained signals.30727-2/fulltext) These debates underscore how initial observational gaps were bridged by converging lines of , prioritizing over unverified confounders.

Response Overreach and Economic Costs

Public health responses to the Zika outbreak included travel advisories and restrictions issued by organizations such as the CDC and WHO, aimed at minimizing importation risks to non-endemic areas. However, these measures had limited impact on preventing imported cases, with local proving more effective in reducing transmission risks, as evidenced by modeling studies showing negligible benefits from broad travel curbs relative to their implementation costs. In the , such alerts contributed to substantial revenue losses, estimated at up to $9 billion over 2015–2017, representing over 80% of the region's total socio-economic impact from the outbreak, or approximately 0.06% of annual GDP. Mass efforts, including widespread fumigation campaigns, incurred significant direct costs—such as the World Bank's $150 million allocation for in 2016—while yielding variable efficacy against mosquitoes, often requiring repeated applications due to incomplete coverage and mosquito behavior. These interventions carried environmental burdens, including non-target impacts on pollinators, aquatic life, and soil ecosystems from and pesticides, prompting calls for integrated approaches to mitigate ecological trade-offs. Opportunity costs arose from resource diversion toward Zika-specific measures, potentially straining surveillance and control for co-endemic diseases like dengue and , which impose higher baseline burdens in the region. The WHO's declaration of Zika as a Emergency of International Concern (PHEIC) on February 1, , and its termination just nine months later on November 22, , underscored a rapid as transmission intensity waned, with reported cases in dropping substantially from 2017–2021. This swift downgrade, amid declining rates and no sustained global escalation, highlighted potential overstatement of long-term risks during peak alarm, as the virus persisted at low endemic levels without necessitating ongoing emergency measures. Economic analyses post-PHEIC affirmed that short-term response expenditures—totaling around $3.5 billion globally in —outweighed proportional benefits when weighed against the outbreak's contained scope and mild symptomatology in most cases.

Media Amplification vs. Actual Risks

During the 2016 Zika outbreak, media coverage escalated dramatically, with U.S. outlets alone publishing thousands of articles that frequently invoked apocalyptic scenarios, such as widespread neurological devastation and travel bans, despite empirical evidence indicating predominantly mild febrile illness in adults resembling other arboviral infections. Symptomatic cases in non-pregnant individuals typically involved self-limiting symptoms like , , and low-grade fever lasting 2–7 days, with severe complications such as Guillain-Barré syndrome confirmed in only about 0.24–1.2 cases per 1,000 infections and an overall below 0.01%. This amplification correlated more closely with spikes in online searches and engagement than with proportional morbidity data, as studies of collective attention dynamics revealed media-driven peaks outpacing actual incidence reports. Conspiracy narratives, including assertions that genetically modified mosquitoes deployed in by engineered the , proliferated online and filled informational voids from delayed virological confirmation, yet genetic sequencing of vectors demonstrated no causal connection, as the modified strains were designed for population suppression and lacked Zika transmission capability. Such theories, often amplified by low-credibility platforms despite refutation by entomological evidence, distracted from verifiable transmission via wild-type species, with inaccurate content garnering disproportionately high views and shares relative to authoritative sources. By 2025, longitudinal reviews of the 2015–2016 epidemic documented a sharp decline in global Zika cases post-2017, with transmission confined to sporadic, low-level circulation in endemic areas, reflecting population-level herd dynamics and underemphasized individual preventive actions like eliminating standing water to disrupt breeding cycles. Retrospectives highlighted regional resilience without sustained hyperendemicity, as immunity waned slowly but —achievable through personal repellents and screens—proved more determinative than hyped systemic interventions, revealing initial coverage's tendency to prioritize novelty over scalable, evidence-based mitigation.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.